AR082620A1 - Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 - Google Patents
Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2Info
- Publication number
- AR082620A1 AR082620A1 ARP110102907A ARP110102907A AR082620A1 AR 082620 A1 AR082620 A1 AR 082620A1 AR P110102907 A ARP110102907 A AR P110102907A AR P110102907 A ARP110102907 A AR P110102907A AR 082620 A1 AR082620 A1 AR 082620A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- phenyl
- amino
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuesto de quinolil amina de acuerdo con la fórmula (1) en la que R1 es H, -SO2-alquilo C1-4, -CO-alquilo C1-4, o alquilo C1-4; R2 es -SRa, -SORa, o -SO2Ra, en los que Ra es alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-7, heterocicloalquilo de 4 - 7 miembros, arilo, o heteroarilo, en los que dicho alquilo C1-6 está opcionalmente sustituido por uno o dos grupos cada uno independientemente seleccionado de ciano, hidroxilo, alcoxi C1-6, alcoxi C1-6-alcoxi C2-6, -CO2H, -CO2-alquilo C1-4, -SO2-alquilo C1-4, cicloalquilo C3-7, fenilo, heteroarilo de 5 - 6 miembros, heteroarilo de 9 - 10 miembros, heterocicloalquilo de 4 - 7 miembros y (fenil)(alquil C1-4)amino-, en los que dicho cicloalquilo C3-7, fenilo, (fenil)(alquil C1-4)amino-, heteroarilo de 5 - 6 miembros, heteroarilo de 9 - 10 miembros o heterocicloalquilo de 4 - 7 miembros están opcionalmente sustituidos por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquilo C1-4 y alcoxi C1-4, dicho cicloalquilo C3-7 o heterocicloalquilo de 4 - 7 miembros está opcionalmente sustituido por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquil C1-4-, oxo y alcoxi C1-4, y dicho arilo o heteroarilo está opcionalmente sustituido por 1 - 3 grupos cada uno independientemente seleccionado de halógeno, -CF3, hidroxilo, amino, alquil C1-4amino-, alquil C1-4-alquil C1-4amino-, alquilo C1-4, fenil-alquil C1-4-, hidroxi-alquil C1-4- y alcoxi C1-4; R3 es metilo, hidroximetilo, trifluorometilo, carboxi, o -CO2-alquilo C1-4; R4 es H, metilo, hidroximetilo, trifluorometilo, carboxi, o -CO2-alquilo C1-4; R5 es H o alquilo C1-3; o una sal o hidrato del mismo. Composición farmacéutica que lo comprende y su uso para preparar un medicamento útil para tratar una enfermedad mediada por la inhibición de la quinasa RIP2. Compuestos útiles para el tratamiento de enfermedades autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37234210P | 2010-08-10 | 2010-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082620A1 true AR082620A1 (es) | 2012-12-19 |
Family
ID=45510458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102907A AR082620A1 (es) | 2010-08-10 | 2011-08-10 | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20120041024A1 (es) |
| EP (1) | EP2603218B1 (es) |
| JP (1) | JP2013533316A (es) |
| AR (1) | AR082620A1 (es) |
| TW (1) | TW201245177A (es) |
| UY (1) | UY33549A (es) |
| WO (1) | WO2012021580A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012225735B2 (en) * | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TWI609011B (zh) * | 2012-08-03 | 2017-12-21 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑的胺基－喹啉 |
| TWI628178B (zh) * | 2012-08-03 | 2018-07-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑的胺基-喹啉 |
| TW201425307A (zh) * | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| AU2014220300B2 (en) | 2013-02-21 | 2016-10-13 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| US10781205B2 (en) | 2016-04-20 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| US9957233B1 (en) | 2016-08-05 | 2018-05-01 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| WO2020094613A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nod2 inhibitors for the treatment of hereditary periodic fevers |
| CN114014890A (zh) * | 2021-03-12 | 2022-02-08 | 爱科诺生物医药(香港)有限公司 | 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3969697A (en) * | 1996-08-01 | 1998-02-25 | Dow Agrosciences Llc | Quinolinium derivatives having fungicidal activity |
| KR100567649B1 (ko) * | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US20030004174A9 (en) * | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE0101675D0 (sv) * | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| BRPI0717320A2 (pt) * | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| TW201425307A (zh) * | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
-
2011
- 2011-08-08 UY UY0001033549A patent/UY33549A/es unknown
- 2011-08-10 TW TW100128463A patent/TW201245177A/zh unknown
- 2011-08-10 AR ARP110102907A patent/AR082620A1/es not_active Application Discontinuation
- 2011-08-10 JP JP2013524193A patent/JP2013533316A/ja not_active Ceased
- 2011-08-10 US US13/206,706 patent/US20120041024A1/en not_active Abandoned
- 2011-08-10 EP EP11816959.8A patent/EP2603218B1/en not_active Not-in-force
- 2011-08-10 WO PCT/US2011/047183 patent/WO2012021580A1/en active Application Filing
-
2014
- 2014-05-21 US US14/283,352 patent/US20140256949A1/en not_active Abandoned
-
2015
- 2015-11-05 US US14/933,201 patent/US20160060249A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2603218B1 (en) | 2016-03-02 |
| EP2603218A4 (en) | 2014-01-15 |
| WO2012021580A1 (en) | 2012-02-16 |
| US20160060249A1 (en) | 2016-03-03 |
| US20120041024A1 (en) | 2012-02-16 |
| JP2013533316A (ja) | 2013-08-22 |
| US20140256949A1 (en) | 2014-09-11 |
| UY33549A (es) | 2012-01-31 |
| EP2603218A1 (en) | 2013-06-19 |
| TW201245177A (en) | 2012-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082620A1 (es) | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 | |
| CY1120703T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| EA201692506A2 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112015008487A2 (pt) | compostos de benzeno substituído | |
| BR112015008447A2 (pt) | métodos para tratar câncer | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| BR112015029455A8 (pt) | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer | |
| BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
| BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
| BR112015020787A2 (pt) | inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico | |
| EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX345238B (es) | (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |